CClinicalTrials.gg
Sign In
CompletedNCT01605578Updated Sep 4, 2025

Description of Abdominal and Gluteo-femoral Subcutaneous Adipose Tissue Cell Population in Women - GLUTAB

An interventional study of Biopsies in Adipose Tissue, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to female participants aged 25 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
25 Years to 45 Years
Sex
Female
01

Study summary

The purpose of this study is to compare, in healthy women, the adipose tissue composition between abdomen and thigh and then determine whether differences exist independently of the state of obesity.

The findings of this study may help to explain the mechanism contributing to a beneficial role of gluteo-femoral fat contrasting with a deleterious role of abdominal fat on cardiovascular and metabolic dysfunctions.

02

Conditions studied

  • Adipose Tissue
03

In context

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 375 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • women between 15 and 45 years old
  • with genital activity
  • stable weight during the previous 3 months
  • BMI from 20 to 28
  • regular menstrual cycles (28 +/- 2 days) during the previous 3 months
  • reliable means of contraception (systemic hormonal contraception, intrauterine contraceptive device, tubal ligation)
  • using the same way of contraception during the previous 3 months
  • normal clinical examination
  • able to be compliant with the schedule of protocol assessments
  • willing and able to provide written informed consent
  • affiliated to a National Health Service
  • agreeing to being registered on the national file for subjects participating in biomedical research

Exclusion Criteria:

  • Exclusions related to significant medical disturbances :
  • type I and II diabetes
  • early menopause
  • serious psychological disorders
  • uncontrolled thyroid disorders
  • know allergy to local anesthetics especially Xylocaine
  • abnormal laboratory results
  • medical history that, in the opinion of the investigator, makes the subject unsuitable for enrollment
  • positive test result for HIV, HCV and/or HBV virus
  • positive pregnancy test
  • Exclusions related to subject lifestyle :
  • smoking > 10 cigarettes per day
  • smoking cessation during the previous 3 months
  • weight fluctuation (>3kg) during the previous 3 months
  • alcohol abuse
  • coffee or tea consumption > 6 cups per day
  • high consumption of drinks comprising xanthine bases (>0.5 liters/day)
  • consumption of drinks (water or herbal teas) > 2 liters per day
  • Exclusions related to previous or concomitant treatments :
  • anticoagulant
  • neuroleptic or antidepressant
  • medication with draining, lipolytic, appetite suppressant and/or slimming effect
  • local or systemic corticosteroid therapy on the test areas
  • hormonal treatment other than contraception
  • diuretic
  • local treatment against cellulitis (mesotherapy,phosphatidylcholine injection, mechanical process)
  • thighs liposuction \< 2 years
  • chronic treatment with anti-inflammatory
  • Exclusions related to the subject :
  • unwillingness or inability to comply with the requirements of the protocol
  • previous participation in a clinical trial within 30 days
  • inability to understand and sign the consent due to linguistic or psychic issues
  • subject deprived of liberty or under guardianship, tutorship or judicial protection
  • female who are currently pregnant or breastfeeding or female considering becoming pregnant while in the study
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Enrollment
20 participants (actual)

Study arms

  • Other
    Non-menoposal healthy volunteer women aged between 25 to 45 years

    Adipose tissue biopsie (2-3g) have been taken by needle biopsy form the abdomen (periumbilical) and gluteo-femoral (upper thigh) levels

    Procedure: Biopsies

Interventions

  • ProcedureBiopsies

    Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies

06

What researchers measure

Primary outcomes

  1. To compare the number and the phenotype of cells between abdominal and gluteo-femoral adipose tissue in women.

    Time frame: There is no time frame. It's a comparison of adipose tissue composition between two locations, collected both at visit 2 (inclusion).

07

Study locations

1 site
  • Centre d'Investigation Clinique, CHU Purpan
    Toulouse, 31059, France
08

References and documents

Publications

  • Gao H, Volat F, Sandhow L, Galitzky J, Nguyen T, Esteve D, Astrom G, Mejhert N, Ledoux S, Thalamas C, Arner P, Guillemot JC, Qian H, Ryden M, Bouloumie A. CD36 Is a Marker of Human Adipocyte Progenitors with Pronounced Adipogenic and Triglyceride Accumulation Potential. Stem Cells. 2017 Jul;35(7):1799-1814. doi: 10.1002/stem.2635. Epub 2017 May 18. PubMed 28470788 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01605578
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
May 25, 2012
Start date
May 14, 2012
Primary completion
Dec 14, 2012
Completion
Dec 14, 2012
Last update
Sep 4, 2025

Study contacts

Claire Thalamas, Doctor
principal investigator · CHU Purpan (Toulouse)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Start the discussion